The Enterprise Value as of September 2024 (TTM) for Viracta Therapeutics, Inc. (VIRX) is 13.49M

According to Viracta Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 13.49M. This represents a change of -67.03% compared to the average of 40.92M of the last 4 quarters.

Viracta Therapeutics, Inc. (VIRX) Historical Enterprise Value (quarterly & annually)

How has VIRX Enterprise Value performed in the past?

The mean historical Enterprise Value of Viracta Therapeutics, Inc. over the last ten years is 78.86M. The current 13.49M Enterprise Value has changed 1.61% with respect to the historical average. Over the past ten years (40 quarters), VIRX's Enterprise Value was at its highest in in the September 2014 quarter at 1.51B. The Enterprise Value was at its lowest in in the March 2021 quarter at 17.37M.

Viracta Therapeutics, Inc. (VIRX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Viracta Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Viracta Therapeutics, Inc. (VIRX) Average Enterprise Value

How has VIRX Enterprise Value performed in the past?

The current Enterprise Value of Viracta Therapeutics, Inc. (VIRX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Viracta Therapeutics, Inc. (VIRX) Enterprise Value vs. Peers

How is VIRX’s Enterprise Value compared to its peers?

Viracta Therapeutics, Inc.’s Enterprise Value is less than Vincerx Pharma, Inc. (15.16M), greater than TRACON Pharmaceuticals, Inc. (-5758866.00), less than Rallybio Corporation (29.25M), less than Tenaya Therapeutics, Inc. (116.79M), less than Lyra Therapeutics, Inc. (22.76M), less than Trevi Therapeutics, Inc. (235.77M), less than SQZ Biotechnologies Company (24.11M), greater than Protara Therapeutics, Inc. (-44987784.00), less than ALX Oncology Holdings Inc. (114.66M), less than Cabaletta Bio, Inc. (47.63M), less than EyePoint Pharmaceuticals, Inc. (409.37M), less than Biomea Fusion, Inc. (211.72M), less than X4 Pharmaceuticals, Inc. (49.50M), less than Mereo BioPharma Group plc (657.97M), less than Inozyme Pharma, Inc. (395.96M), less than Terns Pharmaceuticals, Inc. (770.84M), less than Leap Therapeutics, Inc. (32.20M), less than Bicycle Therapeutics plc (760.78M), less than IGM Biosciences, Inc. (959.77M), less than Monte Rosa Therapeutics, Inc. (300.68M), less than Stoke Therapeutics, Inc. (613.58M),

Build a custom stock screener for Viracta Therapeutics, Inc. (VIRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Viracta Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Viracta Therapeutics, Inc. (VIRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Viracta Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.